A Phase I Dose Escalation Study of LBH589 [panobinostat] in Combination With Imatinib Mesylate for Treatment of Patients With Chronic Myeloid Leukemia in Cytogenetic Remission With Residual BCR-ABL +Cells Detectably by Q-PCR [quantitative-polymerase chain reaction].

Next Previous
Trial Profile

A Phase I Dose Escalation Study of LBH589 [panobinostat] in Combination With Imatinib Mesylate for Treatment of Patients With Chronic Myeloid Leukemia in Cytogenetic Remission With Residual BCR-ABL +Cells Detectably by Q-PCR [quantitative-polymerase chain reaction].

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2014

At a glance

  • Drugs Imatinib; Panobinostat
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Biomarker

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Jul 2012 Planned number of patients changed from 18 to 23 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top